ORPHA:228285
Acquired cutis laxa
Also known as: Cutis laxa acquisita
Publications
200
64.5th percentile
Trials
0
Interventional, condition-specific
Researchers
932
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of the connective tissue characterized by skin inflammation inducing elastolysis, leading to sudden, fine skin wrinkling, and variable systemic involvement.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016446
- UMLS:C0406549
Additional Mondo synonyms (2)
acquired cutis laxa · cutis laxa acquisita
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
200 matched papers (89 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 3 for broader category cutis laxa
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
200
200 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
200 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
89 in the last 10 years · high confidence · 64.5th percentile (publications denominator)
Phrase hits: 200 · MeSH hits: 0
Who's working on it?
932
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Davidson JM3 papers · 1996Papers in Europe PMC
- 02Jiang Y3 papers · 2023
Department of Dermatopathology, Hospital for Skin Diseases and Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu, China.
Papers in Europe PMC - 03Weiss AS3 papers · 2021
Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Papers in Europe PMC - 04Zhao Y3 papers · 2024
Graduate College of Tianjin Medical University, No. 22 Qixiangtai Road, Heping District, Tianjin, 300070, China.
Papers in Europe PMC - 05Abenavoli L2 papers · 2019
Institute of Internal Medicine, Catholic University, L.go Gemelli 8, 00168 Rome, Italy.
Papers in Europe PMC - 06Acosta-Jiménez E2 papers · 2026
Division of Postgraduate Studies, Universidad Nacional Autónoma de México, Mexico City, Mexico; Pathology Department, Hospital de Especialidades Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Papers in Europe PMC - 07Antiga E2 papers · 2023
Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Papers in Europe PMC - 08Baldock C2 papers · 2021
Wellcome Trust Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, School of Biological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
Papers in Europe PMC - 09Beylot-Barry M2 papers · 2021
Department of Dermatology, Hôpital Saint André, Bordeaux, France.
Papers in Europe PMC - 10Bladé J2 papers · 2021
Amyloidosis and Multiple Myeloma Unit, Hospital Clínic, 08036 Barcelona, Spain.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 3 trials are registered for cutis laxa, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
3 interventional trials matched cutis laxa, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: cutis laxa
3
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07614997·RECRUITING·Effectiveness and Safety of the Ulthera® System for Skin Laxity in the Lower Face, Submentum and Neck
Conditions: Cutis Laxa·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acquired cutis laxa" OR "Cutis laxa acquisita"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acquired cutis laxa" OR "Cutis laxa acquisita"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"cutis laxa"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:06:00.956Z